Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: November 13, 2019)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Genetics/Family History

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 2260 miles
Allegheny Health Network (AHN) - Allegheny General Hospital ONLY
Pittsburgh,PA

VISITS: 1 visit a week for 3 weeks, then monthly visits thereafter

PHASE: II

NCT ID: NCT02738866

Palbociclib With Fulvestrant for ER+, HER2- Advanced Breast Cancer

Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor Scientific Title

Purpose
To study the safety and effects (good and bad) of using Ibrance and Faslodex to treat women and men with advanced breast cancer who have previously been treated with Ibrance and an aromatase inhibitor.
Who is this for?
Women and men with ER positive, HER2 negative advanced (some stage III) or metastatic (stage IV) breast cancer and have already been treated with palbociclib (Ibrance®) and an aromatase inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, once daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, once a week for 3 weeks then once a month thereafter</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02738866' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://pubchem.ncbi.nlm.nih.gov/compound/Fulvestrant#section=Top' target='_blank'>PubChem: Fulvestrant</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-us-fda-approval-as-monotherapy-for-expanded-use-in-breast-cancer.html' target='_blank'>AstraZeneca Press Release: Fulvestrant</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancercare.org.uk/information-support/facing-breast-cancer/going-through-breast-cancer-treatment/targeted-therapy/palbociclib-ibrance#what%20is%20palbociclib' target='_blank'>BreastCancerCare UK: Palbociclib</a> </li></ul>
See more